Today, 3-4% of the global population suffer from Obstructive Sleep Apnoea with 94% of these sufferers still waiting to be testing, diagnosed, and prescribed a treatment such a Continuous Positive Airway Pressure (CPAP).
[¹] Aside from excessive tiredness and a general reduced quality of life, undiagnosed sleep disorders such as Obstructive Sleep Apnoea can lead to a number of health problems such as:
Undiagnosed sleep disorders such as Obstructive Sleep Apnoea can also be a cause of or factor in:
¹. David R Hillman, MB, FRCPE, FANZCA; Anita Scott Murphy, BEc; Ral Antic, MB, FRACP; Lynne Pezzullo. (2006). The Economic Cost of Sleep Disorders.
In 2013, the RSA (Road Safety Authority of Ireland), brought in regulations which require sufferers of moderate or severe Obstructive Sleep Apnoea Syndrome causing excessive daytime/awake time sleepiness to cease driving until satisfactory control of symptoms has been attained with ongoing compliance with treatment, confirmed by medical opinion. These sufferers of Sleep Apnoea must then undergo periodic medical reviews, and may only be granted a 1-3 year Driving Licence [²].
Obstructive Sleep Apnoea can have extremely negative lifestyle implications for a sufferer, hindering their independence and quality of life.
Since the launch of RespiraSense in 2014, PMD has conducted research activities to launch a new product in 2016 that seeks to address this undiagnosed 94% of sleep disorder sufferers.
At present, testing for sleep disorders is carried out during an overnight sleep test, during which the patient wears an assortment of belts and nasal cannulas. Such tests can often be quite unpleasant and cause discomfort for the patient.
². National Programme Office for Traffic Medicine, Royal College of Physicians of Ireland (RCPI), Road Safety Authority (RSA),Sláinte agus Tiomáint, Medical Fitness To Drive Guidelines, (Group 1 and Group 2 Drivers), April 2016, 5th Edition.
PMD is developing an alternative to such tests. Leveraging the same technology used for continuous respiratory rate monitoring with RespiraSense, PMD have designed a Home Sleep Test, where the patient simply goes to their doctor/nurse, who then applies the device to the Patient. The Patient then wears the RespiraSense device home, overnight and returns to the clinic the following day to their doctor/nurse to have the device removed.
Within 24 hours of the test being completed, a diagnosis can be made and treatment can be prescribed.
The clinical need for accelerated diagnosis for sleep Apnoea is urgent. Ultimately, PMD’s Home Sleep Test will enable Sleep Consultants to increase their patient coverage by over 200% with a minimum increase in resources.
Fundamentally, PMD seeks to improve Patient outcomes by making every breath count through continuous Respiratory rate monitoring for general care floor and simple Home Sleep Tests for patients around the world. Positioning PMD’s technology as the industry standard in respiratory effort monitoring by 2020.
This product is expected to be market ready by Q2 2017.
Not for sale in the United States.